Canaquest Medical Corporation · OTC:CANQF
Canaquest Medical — Investor Presentation (September 2021)
17 slides from Canaquest Medical's investor presentation, Sep 1, 2021
Slide 1: Mentanine® CBD-based formulation
Therapeutic Potential of CBD Formulated Products backed by Science and Pre-clinical Trials for Neuropsychiatric Disorders Mentanine® CBD-based formulation September 1, 2021
Slide 2: CanaQuest Medical Corp.
CanaQuest Medical Corp. OUR COMPANY A life science and pharmaceutical company developing cannabinoid and botanical-based medical formulations to treat neurological conditions and mental health ailments. OUR VISION To be a global leader in the formulation and development of transformative pharmaceuti
Slide 3: What we do
What we do | Scientifically developed cannabinoid-based Rx drugs • Develop scientific formulations, supported by clinical trials • Obtain Rx drug approvals from the US-FDA, Health Canada and European Medicines Agency • Deliver superior proprietary drug formulations for healthcare C O N F I D E N T I
Slide 4: Current focus
Current focus Pharmaceutical Rx Drug Pipeline • Two master formulations that are pharma drug candidates targeting neurological conditions: CQ-001 Rx and CQ-002 Rx, derived from Mentanine® and Mentabinol® respectively • Four pre-approved clinical trial programs for CQ-001 Rx • Following pre-establish
Slide 5: About Mentanine®
About Mentanine® | Pharmaceutical Grade CBD Omega-3 formulation • Scientifically developed by CanaQuest’s lead scientist and university-based experts in neuroscience • Pre-clinical trial results – published in peer- reviewed European Journal of Neuroscience, Oct 2020 C O N F I D E N T I A L & P R O
Slide 6: The Scientific Difference: Mentanine® vs. CBD
The Scientific Difference | Pre-clinical results Mentanine® vs. CBD Scientifically developed proprietary formula Pure Cannabidiol New pathway discovery: Synergistically attaches to PPAR receptor allowing Higher concentrations required to achieve efficacy CBD to cross the blood-brain barrier to inter
Slide 7: Unique Formulation. Not a Generic Knockoff
Unique Formulation. Not a Generic Knockoff | Comparison with similar FDA approved product Proprietary formulation from Mentanine®, CQ-001 Rx US$650/100ml Pure CBD, Epidiolex® Rx US$1,400/100ml Pending Rx approval: Health Canada (200 days after start of clinical trials); US FDA approved as a drug for
Slide 8: What is next for Mentanine®
What is next for Mentanine® | Commercial roll out and used as formulation base for Rx drug candidate Commercially ready • Medical cannabis product, IP protected, patent pending. • Formulation includes CBD. All other ingredients are approved for human consumption and are categorized as ”GRAS” General
Slide 9: Rx Drug Clinical Trials
Rx Drug Clinical Trials | Preapproved human trials for CQ-001 Rx and CQ-002 Rx candidates TRIAL TRIAL TIME TO OBTAIN DIN & DATE DURATION Rx APPROVALS Clinical trial Dr W. McIntyre 6 months 3 months USA: + 45-52 weeks after trials Epilepsy 60 patients Burnham, after Specifically: Dravet double blind
Slide 10: Pipeline for Future Rx Drugs
Pipeline for Future Rx Drugs | Scientific Research Project Description Specialists Status Neurological Research and pre-clinical trials; Dr Steven Laviolette + team of Ongoing new formulated product 13 scientists Conditions & Mental development with synergistic Health botanicals Focus on anxiety, PT
Slide 11: Scientific Partners & Regulatory Advisors
Scientific Partners & Regulatory Advisors Dr. Steven Laviolette, B.Sc., Ph.D., a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University, Addiction Research Group Dept. of Anatomy & Cell Biology, Dept. of Psychiatry R & D Program - 14 scientists http://www.s
Slide 12: Scientific Partners & Pharmaceutical Advisor
Scientific Partners & Pharmaceutical Advisor Dr. David W.L. Ma, Ph.D. Professor, Department of Human Health and Nutritional Sciences, University of Guelph R & D Program - 5 scientists https://www.uoguelph.ca/hhns/people/dr-david-wl-ma Dr. Ma obtained his PhD in Medical Sciences in 2001 at the Univer
Slide 13: Executive Team & Board of Directors
Executive Team & Board of Directors | 100+ Years of Management & Product Development Experience Richard Rusiniak, Mechanical Engineer, CEO – Director Over 35 years of management, design and process experience. Co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market valua
Slide 14: Contact Information
Contact Information: Paul Ramsay, President 416.704.3040 paul@canaquest.com www.canaquest.com 14
Slide 15: Two Master Formulations
Two Master Formulations | used as formulation bases for Rx drug candidates Mentanine® Mentabinol® • Pharmaceutical Grade CBD Omega-3 proprietary formulation • Pharmaceutical Grade THC + L-Theanine proprietary formulation • Medical cannabis product • Medical cannabis product • Q3, 2021 market launch
Slide 16: About Mentabinol®
About Mentabinol® | Pharmaceutical Grade THC + L-Theanine formulation • Scientifically developed by CanaQuest’s lead scientist and university-based experts in neuroscience • Pre-clinical trial results – published in peer-reviewed journals December 2020 July 2021 CONFIDENTIAL & PROPRIETARY 16
Slide 17: The Scientific Difference: Mentabinol® vs. THC
The Scientific Difference | Pre-Clinical Results Mentabinol® vs. THC Pure THC Scientifically developed proprietary formula Pre-clinical studies showed: Complete blockage of memory impairment Memory impairment & possible long-term cognitive side effects Reduced depression-like and schizophrenia relat
CanaQuest Medical — Investor Presentation (September 2021) on 6ix